Considering unmet medical needs and our technology platform, Auson focuses on improving the existing products to optimize dosing regimens, develop new dosage forms and new indications. These products will be filed using 505(b)(2) regulatory pathway in U.S. and class 2 of drugs registration classification pathway in China.

Auson currently has two granted patents and one clinical trial approval from NMPA. The patented product ASN001 is indicated for the treatment of infantile hemangiomas and has completed Phase I clinical trial in China, and the multi-center Phase II clinical trial is ongoing. The patented ASN008, sustained-released tablet for treating hepatitis B once weekly, has completed Phase I clinical trial in Australia. And the result meets our expectations. 

We have a solid pipeline, including the drug products with the indication of prevention and treatment of venous thrombosis, pulmonary arterial hypertension and other diseases.